Overdiagnosis and Overtreatment of Prostate Cancer

PSA measurement and prostate cancer--overdiagnosis and overtreatment?

BACKGROUND Growing attention is being paid to PSA testing and the risk of overdiagnosis of prostate cancer. This paper investigates how the number of PSA tests has developed over time in Norwegian counties, and relates this development to the incidence of cancer in the various counties and the rates of prostate cancer surgery. METHOD Data on incidence, survival and mortality were obtained fro...

Overdiagnosis and overtreatment

claim that our critique of the randomized screening trials has little merit; that there is no reason to believe that the Canadian study was of better quality than the New York Health Insurance Plan (HIP) study or the Two-County study; and that the prior consensus on mammography was correct. However, their review suffers from erroneous assumptions and biased statistical analyses, and their quota...

Overdiagnosis and Overtreatment of Prostate Cancer and Breast Cancer Due to Screening

Overdiagnosis and overtreatment over time.

Overdiagnosis and overtreatment are often thought of as relatively recent phenomena, influenced by a contemporary combination of technology, specialization, payment models, marketing, and supply-related demand. Yet a quick glance at the historical record reveals that physicians and medical manufacturers have been accused of iatrogenic excess for centuries, if not millennia. Medicine has long ha...

Addressing overdiagnosis and overtreatment in cancer: a prescription for change.

A vast range of disorders--from indolent to fast-growing lesions--are labelled as cancer. Therefore, we believe that several changes should be made to the approach to cancer screening and care, such as use of new terminology for indolent and precancerous disorders. We propose the term indolent lesion of epithelial origin, or IDLE, for those lesions (currently labelled as cancers) and their prec...